REFERENCES
- Lee B S, Lee J H, Kang H G, Hahn H. Ifosfamide nephrotoxicity in pediatric cancer patients. Pediatr Nephrol 2001; 16: 796–799
- Suarez A, McDowell H, Niaudet P, Comoy E. Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report. J Clin Oncol. 1991; 9: 2177–2182
- Risk factors for nephrotoxicity after ifosfamide treatment in children. a UKCCSG Late Effects Group study. Br J Cancer 2000; 82: 1636–1645
- Stroup D F, Berlin J A, Morton S C, et al. for the Meta-analysis of Observational Studies in Epidemiology (MOOSE) Group. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 283: 2008–2012
- Tokuc G, Yalciner A, Kebudi R, Dogan S. Renal dysfunction secondary to ifosfamide treatment in children. J Exp Clin Cancer Res 1997; 16: 227–230
- Ho P, Zimmerman K, Wexler L, Blaney S. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer 1995; 76: 2557–2564
- Caron H, Abeling N, van Gennip A, de Kraker J. Hyperaminoaciduria identifies patients at risk of developing renal tubular toxicity associated with ifosfamide and platinate containing regimens. Med Pediatr Oncol 1994; 22: 153–154
- Rossi R, Pleyer J, Schafers P. Development of ifosfamide induced nephrotoxicity: prospective follow-up in 75 patients. Med Pediatr Oncol 1999; 32: 177–182
- http://www.cclg.org.uk/public/followup/PracticeStatement/index.html [Accessed July 2007]